Channels
All News
In Focus
Special
AI
Bioregnum
Biotech Voices
Cell/Gene Tx
China
Coronavirus
Deals
Diagnostics
Discovery
FDA+
Financing
Health Tech
Law
Letters to the Editor
Manufacturing
Marketing
Nikkei Biotechnology
Opinion
Outsourcing
Peer Review
People
Pharma
R&D
Startups
Weekly
Webinars
Biopharma Jobs
More
Work at Endpoints
Letter to Editors
Editorial Standards
IPO Tracker
Webinars
Events
Sponsored Posts
Advertise
Privacy Policy
Endpoints Merch
About Us
Help
SIGN UP
LOG IN
Backlash: Harvard experts fret over the fallout from FDA’s OK for Sarepta’s controversial Duchenne drug
9 years ago
R&D
China: Fraud not the only reason 1,193 drug applications were withdrawn; Advaxis shares drop
9 years ago
News Briefing
Inovio shares slide after FDA hits it with a hold on lead PhIII HPV program
9 years ago
R&D
New Listeria fears spotlighted as Aduro’s CRS-207 is slapped with partial hold
9 years ago
R&D
Shire bids CTI and its troubled myelofibrosis drug adieu, buying its way out of a deal
9 years ago
R&D
Zeroing in on Merck rival, GSK steps up to the FDA with its top new vaccine prospect
9 years ago
R&D
Merck completes a clinical trial Odyssey, finally bagging an FDA OK for C diff antibody
9 years ago
R&D
Let's rethink Clinton's war on pharma; The FDA can't order the genie back into the magic lamp
9 years ago
Bioregnum
Opinion
Porges to Biogen: I don’t like your neuropathic pain drug; Ex-Moderna exec Bolen joins PureTech as CSO
9 years ago
News Briefing
Cerecor’s $1M Lilly deal put it in the right place at the right time today
9 years ago
R&D
Roche adjusts Avastin franchise defense plans as PhII successor fails a key study
9 years ago
R&D
Hot on the heels of its Bristol-Myers slapdown, Merck scores PhIII bladder cancer success with Keytruda
9 years ago
R&D
Alkermes plots course to the FDA after its depression drug scores success in last-stand PhIII
9 years ago
R&D
Gilead needs a big R&D hit. Here's why claims on NASH fall well short of that
9 years ago
R&D
Investors add $17M to Emulate Series B as Covance partners; UMass professor to work with Spark on next-gen vectors
9 years ago
News Briefing
Backed by neuro enthusiast Arch, upstart BlackThorn tackles some tough targets with $40M round
9 years ago
R&D
Rigel’s 2nd PhIII for fostamatinib scuttled by a single placebo response, shares crater
9 years ago
R&D
No surprise: AbbVie turns cold shoulder to a messy rheumatoid arthritis partnership with Ablynx
9 years ago
R&D
Eli Lilly wins a quick OK for new sarcoma drug olaratumab
9 years ago
R&D
Now that Sarepta has bolted out of the barn, the FDA wants to shut the door
9 years ago
Bioregnum
R&D
Liver tox cases force Daiichi Sankyo to curtail recruitment for PhIII trial of a ‘breakthrough’ drug
9 years ago
R&D
Novartis throws Cerulean a lifeline with $5M deal; Porges disses Celgene’s GED-0301
9 years ago
News Briefing
Cancer powerhouse Roche elbows its way into a checkpoint showdown with Bristol-Myers, Merck
9 years ago
R&D
Oxford spinout Argonaut looks to hack cancer cells and program them to die
9 years ago
R&D
First page
Previous page
1158
1159
1160
1161
1162
1163
1164
Next page
Last page
Confirm Profile
Full Name
Email
Company
Job Title
{@!--CONSENT--!@}
Submit